Literature DB >> 2335037

Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation.

I T Mak1, W B Weglicki.   

Abstract

The antiperoxidative activities of nifedipine, verapamil, and diltiazem were compared with that of propranolol by using an in vitro model of sarcolemmal membrane lipid peroxidation. Highly purified sarcolemmal membranes, isolated from canine ventricular myocytes, were peroxidized by a superoxide anion-producing and iron-catalyzed free radical-generating system (dihydroxy-fumarate plus FeCl3 and ADP). Lipid peroxidation after 20 minutes of incubation was monitored by malondialdehyde formation. Similar to propranolol, all three calcium blockers exhibited concentration-dependent (10-400 microM) inhibitory effects against sarcolemmal lipid peroxidation. The order of potency of these agents was nifedipine greater than propranolol greater than verapamil greater than diltiazem. Nifedipine, the most effective calcium blocker, was greater than twofold more potent than propranolol and achieved a significant effect at 10 microM. This study suggests that calcium blockers may provide antiperoxidative protection to cardiac membranes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2335037     DOI: 10.1161/01.res.66.5.1449

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  20 in total

1.  Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals.

Authors:  C Napoli; M Chiariello; G Palumbo; G Ambrosio
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

2.  Effects of felodipine on the ischemic heart: insight into the mechanism of cytoprotection.

Authors:  R Ferrari; A Cargnoni; P Bernocchi; G Gaia; M Benigno; E Pasini; P Pedersini; C Ceconi
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

3.  Verapamil attenuates scopolamine induced cognitive deficits by averting oxidative stress and mitochondrial injury - A potential therapeutic agent for Alzheimer's Disease.

Authors:  Saravanaraman Ponne; Chinnadurai Raj Kumar; Rathanam Boopathy
Journal:  Metab Brain Dis       Date:  2019-11-05       Impact factor: 3.584

4.  Hypertrophic Cardiomyopathy: A Vicious Cycle Triggered by Sarcomere Mutations and Secondary Disease Hits.

Authors:  Paul J M Wijnker; Vasco Sequeira; Diederik W D Kuster; Jolanda van der Velden
Journal:  Antioxid Redox Signal       Date:  2018-04-11       Impact factor: 8.401

5.  Ca2+-antagonists inhibit the N-methyltransferase-dependent synthesis of phosphatidylcholine in the heart.

Authors:  P S Tappia; K Okumura; K Kawabata; K R Shah; M S Nijjar; V Panagia; N S Dhalla
Journal:  Mol Cell Biochem       Date:  2001-05       Impact factor: 3.396

6.  Beneficial effects of felodipine on myocardial and coronary function during low-flow ischemia and reperfusion.

Authors:  E A Bernstein; F R Eberli; A M Silverman; G L Horowitz; C S Apstein
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

7.  Impaired endothelium-dependent relaxation of dog coronary arteries after myocardial ischaemia and reperfusion: prevention by amlodipine, propranolol and allopurinol.

Authors:  C G Sobey; R A Dalipram; G J Dusting; O L Woodman
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

8.  Inhibitory effects of calcium antagonists on mitochondrial swelling induced by lipid peroxidation or arachidonic acid in the rat brain in vitro.

Authors:  M Takei; M Hiramatsu; A Mori
Journal:  Neurochem Res       Date:  1994-09       Impact factor: 3.996

9.  Effect of illuminated nifedipine, a potent antioxidant, on intestinal and vascular smooth muscles.

Authors:  V Bauer; V V Rekalov; I Juránek; D Gergel; P Bohov
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

10.  Effects of beta-blockers and Ca(2+)-antagonists on the response of the isolated working rat heart to adrenergic stimulants after cardioplegic arrest.

Authors:  P Hattingh; A Coetzee; I Harper; S Genade; A Lochner
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.